Therefore, our studies indicate that pharmacologically targeting PTP1B and PTPN2 with Compound 182 might not only recruit and activate T cells to repress the growth of immunologically cold tumors, but also sensitize otherwise resistant tumors to PD-1 checkpoint blockade to synergistically promote anti-tumor immunity. Here, PTPN1 is linked to neoplasm.